

DAFTAR PUSTAKA

- Abdul Aziz, A.A., Md Salleh, M.S., dan Ankathil, R., 2020. Clinicopathological and Prognostic Characteristics of Malaysian Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy Regimen. *International Journal of Breast Cancer*, **2020**: 8424365.
- Abdul-Rahman, T., Dunham, A., Huang, H., Bukhari, S.M.A., Mehta, A., Awuah, W.A., dkk., 2023. Chemotherapy Induced Cardiotoxicity: A State of the Art Review on General Mechanisms, Prevention, Treatment and Recent Advances in Novel Therapeutics. *Current Problems in Cardiology*, **48**: 101591.
- Adel, A.M., Abdelaziz, H., Diab, D.R., Gaddalla, M.M., dan Mostafa, M.Y., 2022. Platinum-based versus Anthracyclin-based Neoadjuvant Chemotherapy in Non-metastatic Triple Negative Breast Cancer (TNBC) Patients. *Ain Shams Medical Journal*, **73**: 511–520.
- Allen, K., Lohrisch, C.A., Le, D., Diocee, R.M., Speers, C., Nichol, A., dkk., 2021. Survival following locoregional recurrence in breast cancer by clinical subtype. *Journal of Clinical Oncology*, **39**: 543–543.
- Almansour, N.M., 2022. Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. *Frontiers in Molecular Biosciences*, **9**: 836417.
- Aly, A., Shah, R., Hill, K., dan Botteman, M.F., 2019. Overall Survival, Costs and Healthcare Resource Use by Number of Regimens Received in Elderly Patien. *Future Oncol.*, **15**: 1007–1020.
- Andayani, T.M., 2013. *Farmakoekonomi Prinsip Dan Metodologi*. Bursa Ilmu, Yogyakarta.
- Baranova, A., Krasnoselskyi, M., Starikov, V., Kartashov, S., Zhulkevych, I., Vlasenko, V., dkk., 2022. Triple-negative breast cancer: current treatment strategies and factors of negative prognosis. *Journal of Medicine and Life*, **15**: 153–161.
- Bayoumi, Y., Gaber, A.A., Abdelsaid, A., dan Radwan, A., 2014. Locoregional recurrence of triple-negative breast cancer: effect of type of surgery and adjuvant postoperative radiotherapy. *Breast Cancer: Targets and Therapy*, 151.

- Ben-Aharon, O., Magnezi, R., Leshno, M., dan Goldstein, D.A., 2019. Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers? *The Oncologist*, **24**: 1469–1478.
- Bianchini, G., Balko, J.M., Mayer, I.A., Sanders, M.E., dan Gianni, L., 2016. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. *Nature Reviews. Clinical Oncology*, **13**: 674–690.
- Borri, F. dan Granaglia, A., 2021. Pathology of triple negative breast cancer. *Seminars in Cancer Biology*, **72**: 136–145.
- Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., dkk., 2024. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, **74**: 229–263.
- Chen, Y., Guan, Y., Wang, J., Ma, F., Luo, Y., Chen, S., dkk., 2020. Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China. *International Journal of Cancer*, **147**: 3490–3499.
- Clark, B.Z., Onisko, A., Assylbekova, B., Li, X., Bhargava, R., dan Dabbs, D.J., 2019. Breast cancer global tumor biomarkers: a quality assurance study of intratumoral heterogeneity. *Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc*, **32**: 354–366.
- Clark, T.G., Bradburn, M.J., Love, S.B., dan Altman, D.G., 2003. Survival analysis part I: basic concepts and first analyses. *British Journal of Cancer*, **89**: 232–238.
- da Costa, R., Passos, G.F., Quintão, N.L.M., Fernandes, E.S., Maia, J.R.L.C.B., Campos, M.M., dkk., 2020. Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives. *British Journal of Pharmacology*, **177**: 3127–3146.
- Das, A., Lin, T.A., Lin, C., Meirson, T., McCaw, Z.R., Tian, L., dkk., 2023. Assessment of Median and Mean Survival Time in Cancer Clinical Trials. *JAMA Network Open*, **6**: e236498.
- Egger, S.J., Chan, M.M.K., Luo, Q., dan Wilcken, N., 2020. Platinum-containing regimens for triple-negative metastatic breast cancer. *The Cochrane Database of Systematic Reviews*, **10**: CD013750.
- Febriani, A. dan Rahmawati, Y., 2019. Efek Samping Hematologi Akibat Kemoterapi dan Tatalaksananya. *Jurnal Respirasi*, **5**: 22.

- Feng, W., He, Y., Xu, Jingsi, Zhang, H., Si, Y., Xu, Jiaxuan, dkk., 2022. A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer. *Anti-Cancer Drugs*, **33**: e52–e60.
- Floyd, J. dan Kerr, T.A., 2025. 'Hepatotoxicity of chemotherapy and other cytotoxic agents - UpToDate'. URL: <https://www.uptodate.com/contents/hepatotoxicity-of-chemotherapy-and-other-cytotoxic-agents> (diakses tanggal 15/7/2025).
- Freedman, G.M., 2010. Local-Regional Recurrence of Triple Negative Breast Cancer after Breast-Conserving Surgery and Radiation.
- Gaol, D.L.H.L., Rizki, K.A., dan Soemitro, M.P., 2023. Incidence Rate and Clinical Characteristics of Triple Negative Breast Cancer Patients in Hasan Sadikin Hospital, for the Last Five Years. *Journal of Social Research*, **2**: 1558–1562.
- Ge, J., Zuo, W., Chen, Y., Shao, Z., dan Yu, K., 2021. The advance of adjuvant treatment for triple-negative breast cancer. *Cancer Biology and Medicine*, **18**: 0–0.
- Gradishar, W.J., Moran, M.S., Abraham, J., Abramson, V., Aft, R., Agnese, D., dkk., 2023. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023: Featured Updates to the NCCN Guidelines. *Journal of the National Comprehensive Cancer Network*, **21**: 594–608.
- Gupta, K., Walton, R., dan Kataria, S.P., 2021. Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends. *Cancer Treatment and Research Communications*, **26**: 100278.
- Harborg, S., Zachariae, R., Olsen, J., Johannsen, M., Cronin-Fenton, D., Bøggild, H., dkk., 2021. Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis. *NPJ breast cancer*, **7**: 119.
- Hermansyah, D., Rahayu, Y., Azrah, A., Pricilia, G., Sufida, S., Rifsal, D., dkk., 2021. Triple-Negative Breast Cancer Clinicopathology: A Single-Center Experience. *Indonesian Journal of Cancer*, **15**: 125.
- Holanek, M., Selingerova, I., Bilek, O., Kazda, T., Fabian, P., Foretova, L., dkk., 2021. Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence. *Cancers*, **13**: 1586.
- Holleczeck, B., Stegmaier, C., Radosa, J.C., Solomayer, E.-F., dan Brenner, H., 2019. Risk of loco-regional recurrence and distant metastases of patients with

invasive breast cancer up to ten years after diagnosis - results from a registry-based study from Germany. *BMC cancer*, **19**: 520.

Huang, M., Haiderali, A., Fox, G.E., Frederickson, A., Cortes, J., Fasching, P.A., dkk., 2022. Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review. *Pharmacoeconomics*, **40**: 519–558.

Ismail, U. dan Killeen, R.B., 2025. Taxane Toxicity, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).

Iwase, M., Ando, M., Aogi, K., Aruga, T., Inoue, K., Shimomura, A., dkk., 2020. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer. *Breast Cancer Research and Treatment*, **180**: 687–694.

James, M., Dixit, A., Robinson, B., Frampton, C., dan Davey, V., 2019. Outcomes for Patients with Non-metastatic Triple-negative Breast Cancer in New Zealand. *Clinical Oncology (Royal College of Radiologists (Great Britain))*, **31**: 17–24.

Kaplan, H.G., Malmgren, J.A., dan Atwood, M.K., 2017. Triple-negative breast cancer in the elderly: Prognosis and treatment. *The Breast Journal*, **23**: 630–637.

Kartini, D., Kurnia, A., Jayawinata, Y., Khoe, L.C., dan Marcevianto, K.V., 2021. Ki-67 as a Predicting Factor of Neoadjuvant Chemotherapy Clinical Response for Local Advanced Breast Cancer in Indonesia.

Kemenkes RI, 2013. *Pedoman Penerapan Kajian Farmakoekonomi*.

Kemenkes RI, 2018. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/414/2018 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara.

Kitamura, M., Nakayama, T., Mukaisho, K.-I., Mori, T., Umeda, T., Moritani, S., dkk., 2019. Progression Potential of Ductal Carcinoma in situ Assessed by Genomic Copy Number Profiling. *Pathobiology: Journal of Immunopathology, Molecular and Cellular Biology*, **86**: 92–101.

Korde, L.A., Somerfield, M.R., Carey, L.A., Crews, J.R., Denduluri, N., Hwang, E.S., dkk., 2021. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **39**: 1485–1505.

- Kumar, P. dan Aggarwal, 2016. An overview of triple-negative breast cancer. *Arch Gynecol Obstet*, 247–69.
- Kurtin, S., 2012. Myeloid Toxicity of Cancer Treatment. *Journal of the advanced practitioner in oncology*, **3**: 209–224.
- Lai, E., Persano, M., Dubois, M., Spanu, D., Donisi, C., Pozzari, M., dkk., 2022. Drug-related toxicity in breast cancer patients: a new path towards tailored treatment?—a narrative review. *Precision Cancer Medicine*, **5**: 1–24.
- Lairson, D.R., Parikh, R.C., Cormier, J.N., Chan, W., dan Du, X.L., 2015. Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women. *Value in Health*, **18**: 1070–1078.
- Lee, Prof.K.K.C., Bahri, Dr.S., Talib, Mdm.A., Zainuddin, Dr.J., Aljunid, Prof.D.Dr.S.M., Sulong, Prof.M.Dr.S., dkk., 2012. *Pharmacoeconomic Guideline For Malaysia*. Pharmaceutical Services Division; Ministry of Health Malaysia, Malaysia.
- Lexidrug, 2025. 'UpToDate: Lexidrug - Drug Databases'. URL: <https://online.lexi.com/lco/action/home> (diakses tanggal 15/7/2025).
- Li, F., Zhou, X., Hu, W., Du, Y., Sun, J., dan Wang, Y., 2024. Prognostic predictive value of Ki-67 in stage I–II triple-negative breast cancer. *Future Science OA*, **10**: FSO936.
- Liedtke, C., Kolberg, H.-C., Kerschke, L., Görlich, D., Bauerfeind, I., Fehm, T., dkk., 2018. Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST). *Clinical & Experimental Metastasis*, **35**: 777–783.
- Lin, C., Cui, J., Peng, Z., Qian, K., Wu, R., Cheng, Y., dkk., 2022. Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis. *European Journal of Medical Research*, **27**: 201.
- Litton, J.K., Regan, M.M., Pusztai, L., Rugo, H.S., Tolaney, S.M., Garrett-Mayer, E., dkk., 2023. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. *Journal of Clinical Oncology*, **41**: 4433–4442.
- Łukasiewicz, S., Czezelewski, M., Forma, A., Baj, J., Sitarz, R., dan Stanisławek, A., 2021. Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. *Cancers*, **13**: 4287.

- Makrilia, N., Syrigou, E., Kaklamanos, I., Manolopoulos, L., dan Saif, M.W., 2010. Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review. *Metal-Based Drugs*, **2010**: 1–11.
- Mariotto, A.B., Noone, A.-M., Howlader, N., Cho, H., Keel, G.E., Garshell, J., dkk., 2014. Cancer Survival: An Overview of Measures, Uses, and Interpretation. *JNCI Monographs*, **2014**: 145–186.
- Mason, S.RE., Willson, M.L., Egger, S.J., Beith, J., Dear, R.F., dan Goodwin, A., 2024. Platinum chemotherapy for early triple-negative breast cancer. *The Breast*, **75**: 103712.
- Mattar, A., Antonini, M., Amorim, A.G., Teixeira, M.D., De Resende, C.A.A., Cavalcante, F.P., dkk., 2025. Overall Survival and Economic Impact of Triple-Negative Breast Cancer in Brazilian Public Health Care: A Real-World Study. *JCO Global Oncology*, e2400340.
- Mayer, I.A., Zhao, F., Arteaga, C.L., Symmans, W.F., Park, B.H., Burnette, B.L., dkk., 2021. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **39**: 2539–2551.
- Menon, G., Alkabban, F.M., dan Ferguson, T., 2024. Breast Cancer, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Mittal, S., Khunger, N., dan Kataria, S.P., 2022. Nail Changes With Chemotherapeutic Agents and Targeted Therapies. *Indian Dermatology Online Journal*, **13**: 13–22.
- MOH Malaysia, 2019. Pharmacoeconomic Guidelines for Malaysia Second Edition.
- National Cancer Institute, 2017. Common Terminology Criteria for Adverse Events (CTCAE).
- Ng, J., Sadiq, M., dan Mansoor, Q., 2023. Ocular toxicity following carboplatin chemotherapy for neuroendocrine tumour of the bladder. *Journal of Oncology Pharmacy Practice*, **29**: 768–771.
- NICE, 2013. Guide To The Methods Of Technology Appraisal 2013.
- Nyqvist-Streng, J., Somi, J., Martikainen, J., Olsson, M., Helou, K., Chamalidou, C., dkk., 2025. Age and comorbidity in relation to treatment and survival outcomes in triple-negative breast cancer: A Swedish nationwide registry-based study. *Journal of Geriatric Oncology*, **16**: 102255.

- Oderda, G.M., 2002. The Importance of Perspective in Pharmacoeconomic Analyses. *Journal of Pain & Palliative Care Pharmacotherapy*, **16**: 65–9.
- Orrantia-Borunda, E., Anchondo-Nuñez, P., Acuña-Aguilar, L.E., Gómez-Valles, F.O., dan Ramírez-Valdespino, C.A., 2022. Subtypes of Breast Cancer, dalam: Mayrovitz, H.N. (Ed.), *Breast Cancer*. Exon Publications, Brisbane (AU).
- Oun, R., Moussa, Y.E., dan Wheate, N.J., 2018. The side effects of platinum-based chemotherapy drugs: a review for chemists. *Dalton Transactions (Cambridge, England: 2003)*, **47**: 6645–6653.
- Pagani, M., Bavbek, S., Alvarez-Cuesta, E., Berna Dursun, A., Bonadonna, P., Castells, M., dkk., 2022. Hypersensitivity reactions to chemotherapy: an EAACI Position Paper. *Allergy*, **77**: 388–403.
- Petrelli, F., Bertaglia, V., Parati, M.C., Borgonovo, K., De Silva, P., Luciani, A., dkk., 2023. Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis. *The Breast*, **67**: 8–13.
- Piedra-Delgado, L., Chambergo-Michilot, D., Morante, Z., Fairen, C., Jerves-Coello, F., Luque-Benavides, R., dkk., 2024. Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience. *PLOS ONE*, **19**: e0293833.
- Qin, Z., Ren, G., Yuan, J., Chen, H., Lu, Y., Li, N., dkk., 2020. Systemic Evaluation on the Pharmacokinetics of Platinum-Based Anticancer Drugs From Animal to Cell Level: Based on Total Platinum and Intact Drugs. *Frontiers in Pharmacology*, **10**: 1485.
- Rascati, K.L., 2014. *Essentials of Pharmacoeconomics*, Second edition. ed. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia.
- Rhodes, W.C., Gautam, S., Haiderali, A., Huang, M., Sieluk, J., Skinner, K.E., dkk., 2020. Cost and healthcare resource utilization (HCRU) for patients receiving neoadjuvant therapy for early-stage triple-negative breast cancer (ESTNBC). *Annals of Oncology*, **31**: S51.
- Rommy, 2024. Effectiveness and Safety Profile of Platinum and Non-platinum-based Chemotherapy Drugs in Triple Negative Breast Cancer Patients at Bethesda Hospital Yogyakarta.
- Saleh, R.R., Nadler, M.B., Desnoyers, A., Meti, N., Fazelzad, R., dan Amir, E., 2021. Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis. *Cancer Treatment Reviews*, **100**: 102283.

- Santos, M.L.C., de Brito, B.B., da Silva, F.A.F., Botelho, A.C. dos S., dan de Melo, F.F., 2020. Nephrotoxicity in cancer treatment: An overview. *World Journal of Clinical Oncology*, **11**: 190–204.
- Scott, L.C., Mobley, L.R., Kuo, T.-M., dan Il'yasova, D., 2019. Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014. *Cancer*, **125**: 3412–3417.
- Setiawan, D., Endarti, D., dan Suwantika, A.A., 2017. *Modeling Pharmacoeconomics*. UM Purwokerto Press.
- Siddharth, S. dan Sharma, D., 2018. Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants. *Cancers*, **10**: 514.
- Sieluk, J., Haiderali, A., Huang, M., Yang, L., dan Hirshfield, K.M., 2020. Early triple-negative breast cancer in women aged ≥ 65 : retrospective study of outcomes, resource use and costs, 2010–2016. *Future Oncology*, 1039–1054.
- Skinner, K.E., Haiderali, A., Huang, M., dan Schwartzberg, L.S., 2021. Assessing direct costs of treating metastatic triple-negative breast cancer in the USA. *Journal of Comparative Effectiveness Research*, **10**: 109–118.
- Sun, H., Zou, J., Chen, L., Zu, X., Wen, G., dan Zhong, J., 2017. Triple-negative breast cancer and its association with obesity. *Molecular and Clinical Oncology*, **7**: 935–942.
- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., dkk., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: a cancer journal for clinicians*, **71**: 209–249.
- Suryawati, S., Nadjib, M., Hidayat, B., dan Syam, A.F., 2022. Pedoman Umum Penilaian Teknologi Kesehatan di Indonesia.
- Tian, H., Ma, D., Tan, X., Yan, W., Wu, X., He, C., dkk., 2021. Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review. *Frontiers in Pharmacology*, **12**: 770663.
- Tonin, F.S., Aznar-Lou, I., Pontinha, V.M., Pontarolo, R., dan Fernandez-Llimos, F., 2021. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. *Pharmacy Practice*, **19**: 2302.
- Trisna, Y., 2016. 'Aplikasi Farmakoekonomi'.

- Tzikas, A.-K., Nemes, S., dan Linderholm, B.K., 2020. A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns. *Breast Cancer Research and Treatment*, **182**: 643–654.
- Van Den Ende, N.S., Nguyen, A.H., Jager, A., Kok, M., Debets, R., dan Van Deurzen, C.H.M., 2023. Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. *International Journal of Molecular Sciences*, **24**: 2969.
- Vodithala, S. dan Bhake, A., 2024. Clinicopathology of Triple-negative Breast Cancer: A Study from Tertiary Care Hospital of Central India. *Journal of Datta Meghe Institute of Medical Sciences University*, **19**: 748.
- Vuger, A.T., Tiscoski, K., Apolinario, T., dan Cardoso, F., 2022. Anthracyclines in the treatment of early breast cancer friend or foe? *The Breast*, **65**: 67–76.
- Wahba, H.A. dan El-Hadaad, H.A., 2015a. Current approaches in treatment of triple-negative breast cancer. *Cancer Biol Med.*, **12**: 106–16.
- Wahba, H.A. dan El-Hadaad, H.A., 2015b. Current approaches in treatment of triple-negative breast cancer **12**: .
- Walia, A., Tula, J., dan Prasad, 2023. Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed. *Nature Reviews Clinical Oncology*, **20**: 885–895.
- Wang, C., Kar, S., Lai, X., Cai, W., Arfuso, F., Sethi, G., dkk., 2018. Triple negative breast cancer in Asia: An insider's view. *Cancer Treatment Reviews*, **62**: 29–38.
- Wheeler, S.B., Rotter, J., Gogate, A., Reeder-Hayes, K.E., Drier, S.W., Ekwueme, D.U., dkk., 2023. Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer. *Journal of Clinical Oncology*, **41**: 32–42.
- WHO, 2022. 'Cancer Today'. URL: <https://gco.iarc.who.int/today/> (diakses tanggal 9/3/2024).
- Wu, Q., Ma, G., Deng, Y., Luo, W., Zhao, Y., Li, W., dkk., 2019. Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis. *Frontiers in Oncology*, **9**: 1068.
- Yin, L., Duan, J.-J., Bian, X.-W., dan Yu, S., 2020. Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Research*, **22**: 61.

- Yousefi, M., Assari Arani, A., Sahabi, B., Kazemnejad, A., dan Fazaeli, S., 2014. Household Health Costs: Direct, Indirect and Intangible. *Iranian Journal of Public Health*, **43**: 202–209.
- Yu, J.-H., Lee, J.W., Son, B.H., Kim, S.-W., Park, S.K., Lee, M.H., dkk., 2014. Characteristics of BRCA1/2 Mutation-Positive Breast Cancers in Korea: A Comparison Study Based on Multicenter Data and the Korean Breast Cancer Registry. *Journal of Breast Cancer*, **17**: 129–135.
- Yulian, E.D. dan Fachriza, I., 2024. Five-year survival of triple-negative breast cancer and the associated clinicopathological factors: a study in an Indonesian tertiary hospital. *Medical Journal of Indonesia*, **32**: 230–7.
- Zajączkowska, R., Kocot-Kępska, M., Leppert, W., Wrzosek, A., Mika, J., dan Wordliczek, J., 2019. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. *International Journal of Molecular Sciences*, **20**: 1451.
- Zhang, C., Wang, S., Israel, H.P., Yan, S.X., Horowitz, D.P., Crockford, S., dkk., 2015. Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. *SpringerPlus*, **4**: 386.
- Zhang, C., Xu, C., Gao, X., dan Yao, Q., 2022. Platinum-based drugs for cancer therapy and anti-tumor strategies **12**: 2115–2132.
- Zheng, Y., Tang, M., Deng, Z., dan Cai, P., 2024. Genetic polymorphisms and platinum-induced hematological toxicity: a systematic review. *Frontiers in Pharmacology*, **15**: .